Hodges Kurt B, Lopez-Beltran Antonio, Emerson Robert E, Montironi Rodolfo, Cheng Liang
Department of Pathology and Laboratory Medicine §Urology, Indiana University School of Medicine, Indianapolis, IN 46202, USA.
Appl Immunohistochem Mol Morphol. 2010 Oct;18(5):401-10. doi: 10.1097/PAI.0b013e3181e04816.
Urothelial carcinomas demonstrate diverse morphologic and immunologic features that frequently lead to diagnostic challenges. Recent advances have identified a number of immunohistochemical stains that, when used in the context of a panel, can be a valuable tool in properly classifying primary urothelial carcinoma and carcinomas secondarily involving the urinary bladder. In addition, new biomarkers prove helpful in the staging of bladder carcinoma. In this article, we review the clinical utility of immunohistochemistry in a series of diagnostic scenarios, including flat urothelial lesions with atypia, rare variants of urothelial carcinoma, primary adenocarcinoma versus secondary colorectal tumors, distinguishing prostate from urothelial carcinoma, and the utility of smoothelin in staging bladder carcinoma. Emphasis is placed on panels of commonly used biomarkers to establish diagnoses.
尿路上皮癌表现出多样的形态学和免疫学特征,这常常给诊断带来挑战。最近的进展已经确定了一些免疫组织化学染色剂,当在一组检测中使用时,它们可以成为正确分类原发性尿路上皮癌和继发累及膀胱的癌的有价值工具。此外,新的生物标志物在膀胱癌分期中也很有帮助。在本文中,我们回顾了免疫组织化学在一系列诊断场景中的临床应用,包括非典型扁平尿路上皮病变、尿路上皮癌的罕见变体、原发性腺癌与继发性结直肠肿瘤的鉴别、前列腺癌与尿路上皮癌的区分以及平滑肌肌动蛋白在膀胱癌分期中的应用。重点是使用常用生物标志物组合来进行诊断。